Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.
Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, De U, Jin L, Zhang W, Zheng G, Hromas R, Hann C, Zajac-Kaye M, Kaye FJ, Zhou D. Khan S, et al. Among authors: thummuri d. Cell Death Discov. 2023 Jan 2;9(1):1. doi: 10.1038/s41420-022-01296-8. Cell Death Discov. 2023. PMID: 36588105 Free PMC article.
XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer.
Principe DR, Xiong R, Li Y, Pham TND, Kamath SD, Dubrovskyi O, Ratia K, Huang F, Zhao J, Shen Z, Thummuri D, Daohong Z, Underwood PW, Trevino J, Munshi HG, Thatcher GRJ, Rana A. Principe DR, et al. Among authors: thummuri d. Proc Natl Acad Sci U S A. 2022 Jan 25;119(4):e2116764119. doi: 10.1073/pnas.2116764119. Proc Natl Acad Sci U S A. 2022. PMID: 35064087 Free PMC article.
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Lv D, et al. Among authors: thummuri d. Nat Commun. 2021 Nov 25;12(1):6896. doi: 10.1038/s41467-021-27210-x. Nat Commun. 2021. PMID: 34824248 Free PMC article.
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Thummuri D, et al. Mol Cancer Ther. 2022 Jan;21(1):184-192. doi: 10.1158/1535-7163.MCT-21-0474. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667112 Free PMC article.
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition.
Pal P, Thummuri D, Lv D, Liu X, Zhang P, Hu W, Poddar SK, Hua N, Khan S, Yuan Y, Zhang X, Zhou D, Zheng G. Pal P, et al. Among authors: thummuri d. J Med Chem. 2021 Oct 14;64(19):14230-14246. doi: 10.1021/acs.jmedchem.1c00517. Epub 2021 Sep 17. J Med Chem. 2021. PMID: 34533954 Free PMC article.
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, Khan S, Liu X, Zhang X, Lv D, Song L, Li W, Thummuri D, Yuan Y, Wiegand JS, Ortiz YT, Budamagunta V, Elisseeff JH, Campisi J, Almeida M, Zheng G, Zhou D. He Y, et al. Among authors: thummuri d. Nat Commun. 2020 Apr 24;11(1):1996. doi: 10.1038/s41467-020-15838-0. Nat Commun. 2020. PMID: 32332723 Free PMC article.
34 results